Semaglutide vs Cagrilintide

Semaglutide and Cagrilintide represent two distinct pharmacological strategies for modulating body weight and metabolic function. Semaglutide, a GLP-1 receptor agonist, has been extensively validated in large-scale clinical trials and is approved for type 2 diabetes, obesity, and non-cirrhotic MASH. Cagrilintide, a synthetic amylin analog, is a newer entrant that targets hindbrain satiety circuits. Notably, their combined use in CagriSema has demonstrated synergistic weight loss effects, suggesting complementary mechanisms. This comparison highlights differences in evidence maturity, receptor targets, and safety profiles to guide research design.

Semaglutide is a synthetic GLP-1 receptor agonist with 94% sequence homology to endogenous human GLP-1 (molecular weight ~4113.6 g/mol). It enhances insulin secretion, slows gastric emptying, and reduces appetite via hypothalamic and peripheral pathways. Approved by the FDA in 2017 (Ozempic, Wegovy), its clinical evidence base includes the STEP and SUSTAIN trial programs, which collectively enrolled thousands of participants. Research indicates significant weight loss (up to 15% in some trials), improved glycemic control, and reduced cardiovascular risk in patients with type 2 diabetes. No generic version exists, and the FDA has issued warnings about counterfeit products. Studies suggest dose-dependent gastrointestinal effects, which are typically transient.

Cagrilintide is a long-acting synthetic analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. It acts primarily on hindbrain areas involved in satiety regulation, distinct from GLP-1's hypothalamic and gut-mediated effects. Developed by Novo Nordisk, it is being evaluated both as monotherapy and in fixed-dose combination with semaglutide (CagriSema). In the REDEFINE Phase 3 program, CagriSema achieved 20.4% weight loss at 68 weeks, surpassing semaglutide alone in head-to-head analyses. Novo Nordisk filed for FDA approval in 2026. Preclinical and clinical studies indicate that amylin receptor activation complements GLP-1 signaling, potentially reducing compensatory appetite increases.

Both peptides are primarily studied for weight management and metabolic health, including obesity and insulin resistance. Semaglutide has additional research applications in cardiovascular disease, where trials have shown reduced major adverse cardiac events. Cagrilintide, as a standalone agent, is not yet associated with unique applications beyond metabolic and weight-related endpoints; however, its combination with semaglutide expands the therapeutic scope by targeting dual appetite pathways. Researchers may also explore Cagrilintide's effects on glucose homeostasis and energy expenditure in preclinical models.

Semaglutide: Common adverse events (≥5% in trials) include nausea, vomiting, diarrhea, abdominal pain, and constipation, which are dose-dependent and often transient. Additional effects such as dyspepsia, eructation, flatulence, headache, dizziness, and fatigue have been reported. Serious but rare risks include pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), and severe allergic reactions. Thyroid C-cell tumors have been observed in rodent studies, though relevance to humans remains unclear. Cagrilintide: In the CagriSema group, gastrointestinal adverse events occurred in 79.6% of participants versus 39.9% with placebo, including nausea, vomiting, diarrhea, and constipation. These events were mainly mild-to-moderate and transient. The safety profile mirrors that of GLP-1 receptor agonists, with potential risks for pancreatitis, gallbladder events, and thyroid C-cell tumors in animal models. Researchers should monitor for dose-related tolerability issues.